Mid-Size Pharmaceutical Market Global Research Report 2028

report image

Mid-Size Pharmaceutical Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Formulation (Tablets and Capsules, Injectables, Sprays, and Other formulations), and Therapy Class (Cardiovascular Diseases, Pain Management, Diabetes, Cancer, and Other Conditions)

Publication Month: Jun 2022 | Report Code: TIPRE00018321 | No. of Pages: 203 | Category: Pharmaceuticals | Status: Published

The mid-size pharmaceutical market is expected to grow from US$ 690,105.2 million in 2022 to US$ 1,000,584.3 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.

Revenue, therapy area, R&D expenditure, and reach are among the critical segments of the global pharmaceutical industry. Mid-size pharmaceutical is among the three categories of the pharmaceutical industry. It emphasizes the development of generic drugs and the development of rare disease therapies. The mid-sized pharmaceutical companies have their revenue in the range of US$ 1 billion to US$ 10 billion. The increasing prevalence of chronic diseases, rapidly rising elderly population, and the surging number of products launches and approvals is expected to aid the mid-size pharmaceutical market growth.

The report provides insights and in-depth analysis of the mid-size pharmaceutical market, emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players and the impact of the COVID-19 pandemic on the market across all major regions. The COVID-19 pandemic affected three main aspects of the global economy—manufacturing, supply chain, and financial markets. However, the pandemic impact on the mid-size pharmaceutical market was initially negative, which became positive later. In the beginning of the COVID-19 pandemic, the mid-size pharmaceutical market in the regions faced numerous short-term and long-term challenges, including direct impacts on productions and demands, financial impacts on manufacturing companies, and disruptions in supply chain and markets. In mid-size pharmaceutical markets, the effects of the pandemic were nearly predictable. The result was extremely high demand and funding for products essential to the care and treatment of patients, such as vaccines for infectious diseases, respiratory diseases, diabetes, and influenza. However, budgets for nonessential drugs were limited or unavailable.

Strategic Insights

Report Coverage - Mid-Size Pharmaceutical Market
Report CoverageDetails
Market Size Value inUS$ 690,105.2 Million in 2022
Market Size Value byUS$ 1,000,584.3 Million by 2028
Growth rateCAGR of 6.4% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
No. of Pages203
No. of Tables111
No. of Charts & Figures79
Historical data availableYes
Segments coveredType, Drug Development Type, Formulation, and Therapy Class
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

Since, the regions have quickly changed trial management, most can deliver the clinical trial services as per clients’ needs. Biotech companies are currently initiating clinical trials in the regions. Since the initial outbreak, the situation in Asia Pacific has improved. As of May 2020, 97% of the sites reopened for patient visits, and 83% of the sites are open for on-site CRA visits. Moreover, hospitals in China are 90% open for inpatient/outpatient visits compared to previous years. Also, clinical sites are returning to normal operations.

Based on region, the mid-size pharmaceutical market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

Lucrative Regions for Mid-Size Pharmaceutical Market

Lucrative Regions for Mid-Size Pharmaceutical Market

Get more information on this report :

Market Insights
Increasing Prevalence of Chronic Disorders Drives Mid-Size Pharmaceutical Market

The aging population and changing social behavior contribute to the steady increase in common and costly long-term health problems. With the accelerating urbanization, people are adopting a sedentary lifestyle, which boosts the rates of obesity and cases of illnesses, such as diabetes. According to the World Health Organization, the prevalence of chronic diseases is projected to increase by 57% by 2026. Increasing demand for health care systems due to the rising incidence of chronic illnesses has become a major concern. For instance, according to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to increase to 62 million by 2045. The increase in disease prevalence would be about 35% during the predicted period. Pandemics exert periodic and enormous disruptive strains on fitness systems. Healthcare establishments across the world want to be geared up to collectively comprise outbreaks once they occur. Thus, the increasing prevalence of chronic disorders boosts the mid-size pharmaceutical market growth.

Type-Based Insights

Based on type, the mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. It is expected to be one of the fastest-growing segments. The market growth for the segment is attributed to the increasing budget allocation by pharmaceutical companies for drugs marketing and higher disposable income.

Mid-Size Pharmaceutical Market, by Type – 2022 and 2028

Mid-Size Pharmaceutical Market, by Type – 2022 and 2028

Get more information on this report :

Drug Development Type-Based Insights

Based on drug development type, the mid-size pharmaceutical market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Increasing demand for contract development and manufacturing organizations (CDMOs) and the rising number of new entrants in the market would propel the market growth for the outsource segment during the forecast period.

Formulation-Based Insights

Based on formulation, the mid-size pharmaceutical market is segmented into tablets & capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. The wide usage of tablets and capsules in long-term treatments, easy use of sprays, and innovative injectable formulations, such as prefilled and fixed doses syringes, are anticipated to propel the growth of the market for the tablets & capsules segment during the forecast period.

Therapy Class-Based Insights

Based on therapy class, the mid-size pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Owing to the rising prevalence of chronic diseases and the growing incidence of cancer, the market for the cancer segment is anticipated to grow rapidly during the forecast period.

The mid-size pharmaceutical market players are adopting organic and inorganic strategies, including product launch and expansion, to expand their footprint and product portfolio globally. DAIICHI SANKYO COMPANY, LIMITED; Eisai Co., Ltd.; Regeneron Pharmaceuticals, Inc; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd; Alexion Pharmaceuticals, Inc.; Mallinckrodt; Endo Pharmaceuticals Inc.; Les Laboratories Servier; and UCB S.A. are among the leading companies in the mid-size pharmaceutical market.

Frequently Asked Questions

Mid-size pharmaceutical is among the three categories of pharmaceutical industry. The global pharmaceutical industry is segmented on the basis of their revenue, therapy area, R&D expenditure, reach etc. The mid-sized pharmaceutical companies are those companies which have their revenue in range of US$ 1 billion to US$ 10 billion. Mid-size pharmaceutical emphasizes on generic drug and development of rare disease therapies.
Key factors that are driving the growth of this market are the growing prevalence of prevalence of chronic disorders and rising number of product launches and approvals are expected to drive the market during the forecast period.
The CAGR value of the mid-size pharmaceuticals market during the forecasted period of 2021–2028 is 6.4%.
In 2021, the over-the-counter segment accounted for the largest share of the market; it is further expected to continue its dominance over the forecast period. The major driving factors for the growth of the over-the-counter segment are increasing budget allocation by pharmaceutical companies for the marketing of drugs, higher disposable income, and the rising prevalence of chronic diseases. Moreover, the increasing self-medication tendency among the population is one of the significant factors in the growth of the over-the-counter (OTC) segment.
In 2021, the hip outsource held the largest share of the market, by drug development type. It is expected to report a higher CAGR of 6.7% during 2021–2028.
The mid-size pharmaceuticals market majorly consists of players such as DAIICHI SANKYO COMPANY LIMITED, Eisai Co., Ltd., Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc., Mallinckrodt, Endo Pharmaceuticals Inc., Les Laboratories Servier, UCB S.A. amongst others.
DAIICHI SANKYO COMPANY LIMITED and Regeneron Pharmaceuticals, Inc, are the top two companies that hold huge market shares in the mid-size pharmaceuticals market.

The List of Companies - Mid-Size Pharmaceutical Market

  2. Eisai Co., Ltd.
  3. Bausch Health Companies Inc.
  4. Regeneron Pharmaceuticals, Inc
  5. Sun Pharmaceutical Industries Ltd
  6. Alexion Pharmaceuticals, Inc.
  7. Mallinckrodt
  8. Endo Pharmaceuticals Inc.
  9. Les Laboratories Servier
  10. UCB S.A.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the mid-size pharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global mid-size pharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. 
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount